Annie Yoshiyama - 02 Feb 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: SVP, Finance
Signature: /s/Earl Douglas, Attorney-in-Fact
Issuer symbol: ALLO
Transactions as of: 02 Feb 2026
Net transactions value: -$7,167
Form type: 4
Filing time: 04 Feb 2026, 17:09:39 UTC
Previous filing: 23 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yoshiyama Annie	SVP, Finance	210 EAST GRAND AVE, SOUTH SAN FRANCISCO	/s/Earl Douglas, Attorney-in-Fact	04 Feb 2026	0001835208

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Sale	$7,167	-4,167	-3.1%	$1.72	130,322	02 Feb 2026	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Stock Option (Right to buy)	Award	$0	+179,691		$0.000000	179,691	02 Feb 2026	Common Stock	179,691	$1.87	Direct	F4
transaction	ALLO	Restricted Stock Unit	Award	$0	+50,827		$0.000000	50,827	02 Feb 2026	Common Stock	50,827		Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3	Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program.
F4	25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F5	Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.